Current evidence on the role of lipid lowering drugs in the treatment of psoriasis

被引:15
|
作者
Wang, Jiao [1 ,2 ]
Zhang, Shuo [1 ,2 ]
Xing, Meng [3 ]
Hong, Seokgyeong [1 ,2 ]
Liu, Liu [1 ,2 ]
Ding, Xiao-Jie [1 ,2 ]
Sun, Xiao-ying [1 ,2 ]
Luo, Ying [1 ,2 ]
Wang, Chun-xiao [1 ,2 ]
Zhang, Miao [1 ,2 ]
Li, Bin [2 ,4 ]
Li, Xin [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Dermatol, Shanghai, Peoples R China
[2] Shanghai Acad Tradit Chinese Med, Inst Dermatol, Shanghai, Peoples R China
[3] Shaanxi Hosp Tradit Chinese Med, Dept Dermatol, Xian, Peoples R China
[4] Tongji Univ, Shanghai Skin Dis Hosp, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
lipid metabolism; lipid-lowering drugs; statins; systematic review; meta-analysis; psoriasis; PCSK9; INHIBITION; CARDIOVASCULAR EVENTS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; STATINS; RISK; ATORVASTATIN; INFLAMMATION; RATIONALE;
D O I
10.3389/fmed.2022.900916
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. Objective: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. Methods: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. Results: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): -0.94; 95% CI: [-1.58, -0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: -0.92; 95% CI: [-1.39, -0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20-CCR6 interaction, and reduction in the levels of inflammatory factors. Limitations: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. Conclusion: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] LIPID-LOWERING DRUGS IN TREATMENT OF HYPERLIPEMIA ASSOCIATED WITH NEPHROTIC SYNDROME
    JOVEN, J
    MASANA, L
    VILELLA, E
    TURNER, PR
    LANCET, 1989, 1 (8645): : 1029 - 1029
  • [32] Utilization of lipid-lowering drugs in men and women: a reflection of the research evidence?
    Savoie, I
    Kazanjian, A
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (01) : 95 - 101
  • [33] The short-circuit evidence on lipid-lowering drugs use in pregnancy
    Fogacci, Federica
    Borghi, Claudio
    Cicero, Arrigo F. G.
    ATHEROSCLEROSIS, 2023, 368 : 12 - 13
  • [34] Choice of lipid-lowering drugs
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1042): : 117 - 122
  • [35] Lipid-lowering drugs and cataract
    Bezin, J.
    Mansiaux, Y.
    Pariente, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 6 - 6
  • [36] Pharmacogenetics of lipid-lowering drugs
    Kivisto, K. T.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 47 - 47
  • [37] Carcinogenicity of lipid-lowering drugs
    Laws, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1480 - 1480
  • [38] LIPID-LOWERING DRUGS AND VIOLENCE
    HORROBIN, DF
    BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 : 882 - 883
  • [39] Rhabdomyolysis and lipid-lowering drugs
    Tenenbaum, A
    Fisman, EZ
    Motro, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (12): : 1448 - 1448
  • [40] Lipid-lowering drugs and homocysteine
    Landray, MJ
    Townend, JN
    Martin, S
    Martin, U
    Wheeler, DC
    LANCET, 1999, 353 (9168): : 1974 - 1975